Localized Prostate Cancer Deaths Remain Low After
The death rate in patients with localized prostate cancer remained stable and low after more than 20 years of follow-up, a large retrospective study reported in the May 3 Journal of the American Medical Association (JAMA).
The study is based on a risk analysis of 767 men in the Connecticut Tumor Registry (CTR) diagnosed with prostate cancer between 1971 and 1984 and treated by either observation or delayed androgen withdrawal. "Men with low-grade prostate cancers have a minimal risk of dying from prostate cancer during 20 years of follow-up," note the researchers, who were led by Dr. Peter C. Albertsen of the University of Connecticut Health Center.The study updates and confirms the authors' initial report published in 1998 on the same patient cohort. "Because these men have been followed continuously by the CTR, we had an opportunity to extend our follow-up to 20 years to determine whether prostate cancer mortality rates declined, remained constant, or increased after 15 years," the researchers explain. Read more
Cancer Centers: Providing Leadership and New Opportunities
Yesterday marked the second annual retreat of National Cancer Institute-designated Cancer Center directors. The retreat provides a forum for NCI leaders to brief the directors on important NCI initiatives, and for an open and honest dialogue on the national cancer program.
Just like the inaugural retreat last spring, this year's retreat was gratifying and educational. It allowed NCI leaders to better understand the complexity of the challenges facing Cancer Centers, as well as the breadth of the opportunities before us.
As the recent special issue of the Cancer Bulletin described, NCI-designated Cancer Centers have evolved into the core of the national cancer program. The majority of individual R01 and P01 awards, for example, go to researchers at NCI-designated Cancer Centers, as do the majority of funds for training grants and Specialized Programs of Research Excellence. Read more